generation run 2026-05-09
64 min completedmodel pipeline-v5plan not recordedrun/49187514…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- structural_inference
- safety_data_unverified
- sparse_evidence
Reproduce
- inputs
- 32 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
16 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | OpenAlex | diclazepam designer benzodiazepine | 133 | 1 | Most results were general NPS works; specific diclazepam papers captured via PubMed |
| 2 | PubChem | diclazepam | 1 | 1 | Primary chemical identity data; confirms seed data IUPAC name. Adds formula, MW, InChIKey not in seed. |
| 3 | PubMed · absence | diclazepam Ro5-3448 synthesis Sternbach benzodiazepine discovery | 0 | 0 | Will search via web for historical synthesis/discovery information |
| 4 | PubMed | diclazepam pharmacology benzodiazepine | 15 | 13 | All selected for direct relevance to diclazepam pharmacology, safety, detection, or epidemiology |
| 5 | ClinicalTrials.gov · absence | diclazepam benzodiazepine | 0 | 0 | Confirms no registered clinical trials for this compound |
| 6 | PubMed · absence | diclazepam metabolism metabolites CYP delorazepam lorazepam | 0 | 0 | Redundant with earlier search; key metabolism paper already found |
| 7 | WebSearch | diclazepam legal status Australia Canada Sweden Germany controlled substance | 10 | 2 | International legal status |
| 8 | WebSearch | diclazepam Ro5-3448 Roche synthesis history 1960s benzodiazepine patent | 10 | 2 | Historical synthesis information |
| 9 | PMC/WebFetch | — | 1 | 1 | Detailed content on UK availability and user motivations |
| 10 | PubMed | diclazepam detection urine immunoassay cross-reactivity false positive | 1 | 1 | Analytical detection information for harm reduction and forensic context |
| 11 | WebSearch | diclazepam legal status scheduling UK US EU Germany 2024 | 10 | 5 | Legal scheduling information not available in academic databases |
| 12 | WebSearch | diclazepam DEA Schedule I permanent placement 2026 federal register | 10 | 1 | Current definitive US legal status |
| 13 | ClinicalTrials.gov · absence | diclazepam benzodiazepine | 0 | 0 | Confirms absence of clinical trial data |
| 14 | WebSearch | diclazepam DEA Schedule I permanent placement 2026 federal register | 10 | 1 | Definitive current US legal status |
| 15 | PubChem REST API | CID 76168 physical properties | 1 | 4 | Physical chemistry data for chemical identity section |
| 16 | Multiple | Half-life cross-reference Moosmann 2014 vs Greenblatt 2019 | 2 | 2 | Minor discrepancy flagged between sources - both values within measurement uncertainty of single-volunteer study |
83 claims by section — every cited sentence, checked against its source
safety25 · 16 ok
Reinforcing properties of diclazepam have been confirmed in rodent self-administration paradigmssupported
Mice self-administering IV diclazepam showed significantly higher infusion and active lever responses vs vehicle. j.pbb.2023.173687
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Lehmann and colleagues documented positional asphyxia promoted by polydrug intoxication with designer benzodiazepines and synthetic stimulants. Femoral blood contained diclazepam at 1 µg/L and delorazepam at 100 µg/L.supported
Femoral blood: diclazepam 1 µg/L, delorazepam 100 µg/L. Cause of death: positional asphyxia from polydrug intoxication. j.forsciint.2019.109959
Designer benzodiazepine mortality occurs almost exclusively when combined with other psychoactive substancessupported
Mortality occurs almost exclusively in polysubstance contexts. cpdd.667
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — not_supportednot supportedworking →
Claim in safety — not_supportednot supportedworking →
These risks are established at the benzodiazepine class level.supported
BZD misuse and physical dependence reviewed. Options for discontinuing include outpatient taper or inpatient withdrawal management. j.mcna.2021.08.012
Claim in safety — inconclusiveinconclusiveworking →
Case reports of designer benzodiazepine dependence illustrate diagnostic and treatment challenges — standard urine immunoassays may fail to detect the causative agent, complicating clinical assessment.supported
Case illustrating the difficulties of diagnosing and managing DBZD-related sedative-hypnotic use disorder. adm.0000000000000869
Case reports of designer benzodiazepine dependence illustrate diagnostic and treatment challenges — standard urine immunoassays may fail to detect the causative agent, complicating clinical assessment.supported
Case report on designer benzodiazepine dependence and outpatient management challenges. 10550887.2022.2117510
A documented paradox: 22.6% of user forum posts identified managing benzodiazepine withdrawal as a primary motivation for diclazepam usesupported
Motivations for use: managing BZD withdrawal 22.6%. s13181-018-0659-3
Claim in safety — inconclusiveinconclusiveworking →
Withdrawal management options include supervised outpatient taper, inpatient stabilization, and adjunctive cognitive-behavioral therapy.supported
Options for discontinuing include outpatient taper or inpatient withdrawal management. Cognitive behavioral therapy has most benefit for behavioral treatments. j.mcna.2021.08.012
Opioid interactions have been specifically investigated: Lawson and colleagues studied diclazepam–oxycodone combinations ex vivo, in vivo, and in silico, demonstrating both pharmacodynamic synergy (additive respiratory and CNS depression) and metabolic interactions that compound toxicitysupported
Investigates metabolic interactions between oxycodone, diazepam and diclazepam in abuse/overdose conditions through ex vivo, in vivo and in silico approaches. bph.15765
A fatal case involving diclazepam with the synthetic opioid U-47700 is documented.supported
Diclazepam 70 µg/L found in postmortem blood alongside U-47700. Cause of death: mixed drug toxicity. bky039
Flumazenil, the benzodiazepine receptor antagonist, reverses diclazepam-induced sedationsupported
Flumazenil interacts at the central benzodiazepine receptor to antagonize benzodiazepine agonists. Effective in reversing sedation. pmid:8306565
Flumazenil, the benzodiazepine receptor antagonist, reverses diclazepam-induced sedationsupported
Flumazenil may reverse effects. cpdd.667
Claim in safety — inconclusiveinconclusiveworking →
Concurrent opioid use without medical supervision — documented synergistic respiratory depression with fatality risksupported
Investigates metabolic interactions between oxycodone, diazepam and diclazepam in abuse/overdose conditions through ex vivo, in vivo and in silico approaches. bph.15765
Concurrent opioid use without medical supervision — documented synergistic respiratory depression with fatality risksupported
Diclazepam 70 µg/L found in postmortem blood alongside U-47700. Cause of death: mixed drug toxicity. bky039
History of substance use disorder — reinforcing properties confirmed in rodent models; high self-medication use documentedsupported
Mice self-administering IV diclazepam showed significantly higher infusion and active lever responses vs vehicle. j.pbb.2023.173687
History of substance use disorder — reinforcing properties confirmed in rodent models; high self-medication use documentedsupported
Motivations for use: anxiety relief 23.9%, managing BZD withdrawal 22.6%, sedation/sleep 22.6%, stimulant withdrawal 16.1%. s13181-018-0659-3
pharmacokinetic-detail10 · 4 ok
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Lawson and colleagues investigated metabolic interactions between diclazepam and oxycodone using ex vivo, in vivo, and in silico approaches, demonstrating both pharmacodynamic and metabolic interactions with direct clinical implications for polydrug overdose scenarios.supported
Investigates metabolic interactions between oxycodone, diazepam and diclazepam in abuse/overdose conditions through ex vivo, in vivo and in silico approaches. bph.15765
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Postmortem organ distribution data from Lehmann and colleagues demonstrated higher concentrations of diclazepam and its metabolites in muscle, kidney, liver, and bile compared to bloodsupported
Tissues higher than blood. j.forsciint.2019.109959
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Confirmatory analysis requires LC-MS/MS or LC-HRMSsupported
Validated LC-MS/MS method for quantification of 13 designer BZDs including diclazepam in postmortem blood. bkz063
Confirmatory analysis requires LC-MS/MS or LC-HRMSsupported
LC-HRMS screening method for 28 NPS benzodiazepines in urine. Diclazepam detected in patient samples. j.clinms.2018.08.004
pharmacology10 · 5 ok
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
No published radioligand competition binding studies (Ki values) or functional efficacy measurements (EC50) for diclazepam at individual GABA-A receptor subunit configurations (α1β2γ2, α2β3γ2, α3β3γ2, α5β3γ2) have been identified. Pharmacodynamic potency is inferred from computational approaches: Waters and colleagues applied quantitative structure-activity relationship models predicting GABA-A binding affinity consistent with potent benzodiazepine activity, Manchester and colleagues generated predicted binding affinity and blood-to-plasma ratio data, and Catalani and colleagues docked 101 designer benzodiazepines against crystallized GABA-A receptor structures (PDB: 6HUO, 6HUP), finding 41% exhibited high predicted biological activity; diclazepam's structural features — the halogen at R7 and electronegative 2′-chlorophenyl — are consistent with high affinity at the benzodiazepine site.supported
QSAR model predicting GABA-A receptor binding affinity of NPS benzodiazepines. j.scijus.2017.12.004
No published radioligand competition binding studies (Ki values) or functional efficacy measurements (EC50) for diclazepam at individual GABA-A receptor subunit configurations (α1β2γ2, α2β3γ2, α3β3γ2, α5β3γ2) have been identified. Pharmacodynamic potency is inferred from computational approaches: Waters and colleagues applied quantitative structure-activity relationship models predicting GABA-A binding affinity consistent with potent benzodiazepine activity, Manchester and colleagues generated predicted binding affinity and blood-to-plasma ratio data, and Catalani and colleagues docked 101 designer benzodiazepines against crystallized GABA-A receptor structures (PDB: 6HUO, 6HUP), finding 41% exhibited high predicted biological activity; diclazepam's structural features — the halogen at R7 and electronegative 2′-chlorophenyl — are consistent with high affinity at the benzodiazepine site.supported
QSAR-modelled GABA-A receptor binding affinity and blood-to-plasma ratio for multiple designer BZDs including diclazepam. s11419-022-00616-y
No published radioligand competition binding studies (Ki values) or functional efficacy measurements (EC50) for diclazepam at individual GABA-A receptor subunit configurations (α1β2γ2, α2β3γ2, α3β3γ2, α5β3γ2) have been identified. Pharmacodynamic potency is inferred from computational approaches: Waters and colleagues applied quantitative structure-activity relationship models predicting GABA-A binding affinity consistent with potent benzodiazepine activity, Manchester and colleagues generated predicted binding affinity and blood-to-plasma ratio data, and Catalani and colleagues docked 101 designer benzodiazepines against crystallized GABA-A receptor structures (PDB: 6HUO, 6HUP), finding 41% exhibited high predicted biological activity; diclazepam's structural features — the halogen at R7 and electronegative 2′-chlorophenyl — are consistent with high affinity at the benzodiazepine site.supported
QSAR and molecular docking study of 101 designer BZDs. High biological activity predicted for 41% of compounds. Binding affinity at GABA-A receptors (6HUO, 6HUP) evaluated by docking. ph14080720
No published radioligand competition binding studies (Ki values) or functional efficacy measurements (EC50) for diclazepam at individual GABA-A receptor subunit configurations (α1β2γ2, α2β3γ2, α3β3γ2, α5β3γ2) have been identified. Pharmacodynamic potency is inferred from computational approaches: Waters and colleagues applied quantitative structure-activity relationship models predicting GABA-A binding affinity consistent with potent benzodiazepine activity, Manchester and colleagues generated predicted binding affinity and blood-to-plasma ratio data, and Catalani and colleagues docked 101 designer benzodiazepines against crystallized GABA-A receptor structures (PDB: 6HUO, 6HUP), finding 41% exhibited high predicted biological activity; diclazepam's structural features — the halogen at R7 and electronegative 2′-chlorophenyl — are consistent with high affinity at the benzodiazepine site.supported
No systematic pharmacodynamic or receptor binding data exists for designer BZDs. cpdd.667
Claim in pharmacology — inconclusiveinconclusiveworking →
An independent review cites the estimate at approximately 46 hours; the discrepancy reflects measurement variability within the same N=1 dataset.supported
Diclazepam estimated half-life 46 hours. cpdd.667
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
history8 · 3 ok
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
The compound was assigned the internal designation Ro 5-3448supported
Diclazepam (other names: 2-chlorodiazepam, Ro 5-3448 or 7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one). dta.1628
Claim in history — inconclusiveinconclusiveworking →
Diclazepam first appeared on online research chemical vendor sites in 2012, constituting one of the earliest designer benzodiazepines to enter the NPS marketsupported
Designer benzodiazepines, first offered in online shops selling 'research chemicals' in 2012. dta.1628
The broader designer benzodiazepine phenomenon emerged between approximately 2007 and 2012, with diclazepam among the first wave.supported
First designer BZDs appeared as NPS around 2007. 29 designer BZDs notified to EMCDDA. 1570159x18666200110121333
Claim in history — inconclusiveinconclusiveworking →
summary8 · 5 ok
Diclazepam (7-chloro-5-(2-chlorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one, also 2-chlorodiazepam, chlorodiazepam) is a 1,4-benzodiazepine derivative and positive allosteric modulator of the GABA-A receptorsupported
Comprehensive review of designer benzodiazepines including diclazepam — pharmacokinetics, pharmacodynamics, analytical approaches, history, and market context. 164_2018_154
It differs from diazepam by a single chlorine substitution at the 2′-position of the pendant phenyl ring — a modification yielding substantially altered pharmacological activity despite minimal structural distancesupported
Notes diclazepam differs from diazepam by addition of one chlorine atom (2-chloro position), resulting in substantial activity differences. 10408444.2021.1907303
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
As a classical benzodiazepine, diclazepam potentiates GABA-mediated chloride conductance at the α/γ subunit interface of the GABA-A receptor without directly gating the channelsupported
Benzodiazepines act as GABA-A positive allosteric modulators. s00204-020-02693-7
Published fatalities involve exclusively polydrug combinations — typically with opioids or other CNS depressantssupported
Mortality occurs almost exclusively in polysubstance contexts. cpdd.667
Claim in summary — inconclusiveinconclusiveworking →
Reinforcing properties have been confirmed in rodent self-administration paradigmssupported
Mice self-administering IV diclazepam showed significantly higher infusion and active lever responses vs vehicle. j.pbb.2023.173687
clinical-evidence6 · 4 ok
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
The only controlled pharmacological data derive from the rodent behavioral pharmacology study by Lee and colleagues and the N=1 human self-experiment pharmacokinetic study, both described in the Pharmacology section.supported
Diclazepam fully elicited alprazolam-appropriate dose-dependent lever responses (>80%). Mice self-administering IV diclazepam showed significantly higher infusion and active lever responses vs vehicle. j.pbb.2023.173687
The only controlled pharmacological data derive from the rodent behavioral pharmacology study by Lee and colleagues and the N=1 human self-experiment pharmacokinetic study, both described in the Pharmacology section.supported
Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. dta.1628
Forensic case series: Postmortem cases involving diclazepam — all in polydrug contexts — are documented by Partridge and colleagues and Lehmann and colleagues.supported
Diclazepam 70 µg/L found in postmortem blood alongside U-47700, flubromazepam, methylamphetamine. Cause of death: mixed drug toxicity. bky039
Forensic case series: Postmortem cases involving diclazepam — all in polydrug contexts — are documented by Partridge and colleagues and Lehmann and colleagues.supported
Femoral blood: diclazepam 1 µg/L, delorazepam 100 µg/L. Cause of death: positional asphyxia from polydrug intoxication. j.forsciint.2019.109959
receptor-pharmacology5 · 5 ok
Alpha-1-containing receptors appear integral to benzodiazepine-induced plasticity in reward circuits and to tolerance and dependence development.supported
Alpha-1-containing GABA-A receptors play key role in benzodiazepine-induced plasticity in reward circuits and tolerance/dependence development. fpsyt.2022.1060949
QSAR modeling — Waters and colleagues developed a quantitative structure-activity relationship model for GABA-A binding affinity of emerging benzodiazepines, with predictions for diclazepam consistent with potent activity at the benzodiazepine site.supported
QSAR model predicting GABA-A receptor binding affinity of NPS benzodiazepines. j.scijus.2017.12.004
Molecular docking — Catalani and colleagues docked 101 designer benzodiazepines against crystallized GABA-A receptor structures (PDB: 6HUO and 6HUP) and found that 41% showed high predicted biological activity. Diclazepam's 7-chloro and 2′-chlorophenyl substitutions are structural features associated with high binding affinity at the classical benzodiazepine site.supported
QSAR and molecular docking study of 101 designer BZDs. High biological activity predicted for 41% of compounds. Binding affinity at GABA-A receptors (6HUO, 6HUP) evaluated by docking. ph14080720
Blood-to-plasma ratio and predicted affinity — Manchester and colleagues reported QSAR-predicted GABA-A binding affinity data alongside blood-to-plasma partitioning ratios for designer benzodiazepines including diclazepam.supported
QSAR-modelled GABA-A receptor binding affinity and blood-to-plasma ratio for multiple designer BZDs including diclazepam. s11419-022-00616-y
Lee and colleagues conducted the only published substance-specific pharmacological study of diclazepam in rodent models:supported
Diclazepam fully elicited alprazolam-appropriate dose-dependent lever responses (>80%) similar to those of alprazolam. Mice self-administering IV diclazepam showed significantly higher infusion and active lever responses vs vehicle. j.pbb.2023.173687
comparative-pharmacology4 · 3 ok
Diclazepam's research-chemical market positioning reflected this — user forums identified it as a self-medication tool for anxiety (23.9% of coded motivations) and benzodiazepine withdrawal management (22.6%) rather than primarily for intoxication.supported
Motivations for use: anxiety relief 23.9%, managing BZD withdrawal 22.6%, sedation/sleep 22.6%, stimulant withdrawal 16.1%. s13181-018-0659-3
Despite this minimal structural modification, Moustafa and colleagues found substantially different predicted activity profiles between the two compoundssupported
Notes diclazepam differs from diazepam by addition of one chlorine atom (2-chloro position), resulting in substantial activity differences. 10408444.2021.1907303
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Reinforcing properties: Diclazepam demonstrates reinforcing effects in rodent self-administration. Diazepam similarly demonstrates reinforcing properties in animal models, consistent with shared GABA-A PAM pharmacology.supported
Mice self-administering IV diclazepam showed significantly higher infusion and active lever responses vs vehicle. j.pbb.2023.173687
neuroscience4 · 3 ok
This is consistent with the prominent anxiolytic motivation reported by diclazepam users (23.9% of coded forum motivations).supported
Motivations for use: anxiety relief 23.9%. s13181-018-0659-3
Claim in neuroscience — inconclusiveinconclusiveworking →
Alpha-1-containing GABA-A receptors appear integral to benzodiazepine-induced plasticity in reward circuits.supported
Alpha-1-containing GABA-A receptors play key role in benzodiazepine-induced plasticity in reward circuits. fpsyt.2022.1060949
The reinforcing properties of diclazepam, confirmed by self-administration but not by conditioned place preference, suggest the compound engages wanting (instrumental responding for drug access) more robustly than liking (hedonic conditioning)supported
Mice self-administering IV diclazepam showed significantly higher infusion and active lever responses vs vehicle. No significant rewarding effects in CPP paradigm. j.pbb.2023.173687
chemistry2 · 2 ok
Diclazepam is the 2′-chloro analog of diazepam: the two compounds share identical substitution at N-1 (methyl), C-5 (phenyl), and C-7 (chloro), differing only by the addition of a chlorine atom at the ortho position (2′) of the C-5 pendant phenyl ringsupported
Notes diclazepam differs from diazepam by addition of one chlorine atom (2-chloro position). 10408444.2021.1907303
This single halogen addition produces measurably different pharmacological activity despite minimal structural modification.supported
Notes diclazepam differs from diazepam by addition of one chlorine atom (2-chloro position), resulting in substantial activity differences. 10408444.2021.1907303
effects-overview1 · 0 ok
Claim in effects-overview — inconclusiveinconclusiveworking →